The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

EHA 2019 | Mechanisms of resistance to IMiDs in MM

Jun 18, 2019

At the 24th Congress of the European Hematology Association (EHA), Enrique Ocio from the Marqués de Valdecilla University Hospital, Santander, ES, talks about mechanisms of resistance to immunomodulatory drugs (IMiDs) in multiple myeloma (MM).

Enrique Ocio discusses the involvement of cereblon in resistance to IMiDs, concluding that whilst it is an important in some patients, it is not the only factor. Using combination approaches may, in future, avoid the development of resistance, though it is important that we have alternative approaches to treat resistant patients.

Mechanisms of resistance to IMiDs in MM